Related Experiment Videos
[Is Etolip suitable for treatment of various types of hyperlipoproteinemias?]
J Kollár1, V Rozdobud'ková, J Koprovicová
1Ustav experimentálnej medicíny Lekárskej fakulty P. J. Safárika Kosice.
Insights
Etolip, a Czechoslovak hypolipidaemic drug, effectively reduced serum triacylglycerol and cholesterol levels in patients with hyperlipoproteinaemia. The study found significant reductions in lipid concentrations after one month of treatment.
Area of Science:
- Pharmacology
- Clinical Medicine
- Biochemistry
Context:
- Hyperlipoproteinaemia (HL) poses significant cardiovascular risks.
- Existing treatments have varying efficacy and side effect profiles.
- Etolip (ethophylline clofibrate) is a novel Czechoslovak hypolipidaemic agent.
Purpose:
- To evaluate the efficacy and safety of Etolip in treating hyperlipoproteinaemia.
- To assess the impact of Etolip on serum lipid profiles and other biochemical markers.
Summary:
- Etolip (500 mg/day) was administered to 39 manual workers with various types of hyperlipoproteinaemia.
- Significant reductions were observed in serum triacylglycerol (TG) by 28% and total cholesterol (CH) by 11.4% in most HL types.
- Apolipoprotein B also declined significantly, while blood sugar, creatinine, and uric acid levels remained stable. AST and ALT levels doubled but remained borderline.
Impact:
- Etolip demonstrates potential as an effective treatment for hyperlipoproteinaemia, particularly for reducing TG and CH.
- Further research is warranted to explore its long-term effects and safety profile.
- This study contributes to the understanding of hypolipidaemic drug efficacy in a clinical setting.
Abstract:
Etolip is the first Czechoslovak hypolipidaemic preparation produced in the Pharmaceutical Research Institute in Modra. As to the chemical structure it is ethophylline clofibrate. It was administered to 39 manual workers with hyperlipoproteinaemia type IIa, IIb, III, IV and V-500 mg/day, i.e. 2-0-2 capsules. The mean age of the patients varied round 43 +/- 6.1 years. They were subdivided into study possible, comparing Lipanthyl and Etolip. Despite the fact that the subjects did not adhere to a strict diet and occasionally consumed 50-100 g alcohol, Etolip (E) reduced the triacylglycerol concentration (TG) in serum for a period of one month after administration on average by 28% (p less than 0.01) in workers with hyperlipoproteinaemia (HL) type IIb, III, IV and V. In group A it is reduced from 2.8 +/- 1.0 mmol/l to 1.7 +/- 0.5 mmol/l and in group B from 2.4 +/- 1.0 mmol/l to 2.0 +/- 1.0 mmol/l. The total cholesterol concentration (CH) in serum declines after E on average in both groups by 11.4% (p less than 0.01) in the mentioned types of HL, whereby in subjects with HL type IIa and III it is practically unchanged. The apolipoprotein B concentration declines in serum of groups A and B from 185.6 +/- 37.8 to 137.5 +/- 44.2 mg/dl and from 144.9 +/- 27.9 to 113.3 +/- 23.6 mg/dl. After one month treatment with this drug the blood sugar level, and serum creatinine concentration does not rise, the haemogram and the uric acid concentration do not change. E raises the AST and ALT concentration to double the initial value which is still at the borderline of normal values.